Abstract
Dalbavancin is a lipoglycopeptide antibiotic with activity against Grampositive pathogens and a long half-life allowing for weekly dosing. DISCOVER 1 and 2 were identically designed clinical trials of dalbavancin versus vancomycin (VAN) with option to switch to oral linezolid for the treatment of ABSSSI. We evaluated outcomes of ABSSSI in patients treated with VAN by dosing regimen utilized and serum trough concentrations for VAN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
